NasdaqGS:QUREBiotechs
uniQure (QURE) Faces FDA Rebuke, Lawsuits Over AMT-130 Disclosures Is Its Credibility at Risk?
In recent weeks, uniQure has come under pressure as the FDA publicly rebuked its disclosures around AMT-130’s pivotal study design, prompting multiple securities class action lawsuits alleging misleading statements about regulatory interactions and Biologics License Application timelines.
These disputes cut to the core of uniQure’s credibility on its lead Huntington’s disease gene therapy, raising questions about how accurately management has portrayed the program’s regulatory path to...